Additional stem cell therapy for graft failure after allogeneic bone marrow transplantation

Area of Science:

• Hematology
• Transplantation Immunology
• Oncohematology

Background:

• Allogeneic bone marrow transplantation (BMT) can be complicated by graft failure.
• Graft failure necessitates salvage strategies to restore hematopoiesis and improve patient outcomes.
• Donor lymphocyte infusions (DLIs) are used, but a boost of stem cells without further conditioning is an alternative approach.

Purpose of the Study:

• To evaluate the efficacy and outcomes of administering a boost dose of donor stem cells without additional chemotherapy or total body irradiation in patients with graft failure after BMT.
• To assess the rates of hematological recovery, graft-versus-host disease (GVHD), and overall survival following this boost treatment.

Main Methods:

• Retrospective analysis of 20 patients who received a donor stem cell boost after allogeneic BMT between 1983 and 1999.
• Patients received a median booster mononuclear cell dose of 2.55 x 10^8/kg.
• No conditioning regimen was given to 11 patients; others received varying regimens including total nodal irradiation (TNI) and antithymocyte globulin (ATG).

Main Results:

• Fifteen of 20 (75%) patients achieved hematological recovery after the boost.
• Acute GVHD (>= grade II) occurred in 30% of patients, and chronic GVHD in 31.3%.
• Overall survival rates at 1 and 3 years were estimated at 80% and 71%, respectively; survival was significantly lower in primary graft failure cases (p=0.0176).

Conclusions:

• Reinfusion of donor stem cells as a boost is a frequently successful strategy for achieving engraftment in patients with graft failure post-BMT.
• This approach is associated with a low incidence of fatal GVHD and demonstrates relatively good long-term survival.
• The success of stem cell boosts highlights their potential as a valuable salvage therapy in allogeneic transplantation.